ArticleJournal of echocardiography2026
Utility of echocardiographic parameters in predicting cardiac immune-related adverse events in Japanese patients undergoing immune checkpoint inhibitor therapy.
Article in Journal of echocardiography, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune checkpoint inhibitors (ICIs) have transformed cancer treatment but are associated with immune-related adverse events, including cardiac immune-related adverse events (cardiac irAEs). Early identification of patients at risk for cardiac irAEs is crucial, and echocardiographic parameters may serve as valuable predictors. This study aimed to evaluate the predictive utility of echocardiographic indices in assessing cardiac irAE risk in Japanese patients receiving ICI therapy.
methodsThis retrospective study analyzed patients treated with ICIs at the University of Fukui Hospital between November 2015 and October 2018. Cardiac irAEs were defined according to the ESC guidelines.
resultsAmong 73 patients, six (8%) developed cardiac irAEs, with no fatalities. Echocardiographic assessment before ICI initiation revealed that patients who later developed cardiac irAEs had significantly lower ejection fractions (EFs) (p < 0.05). Receiver operating characteristic analysis demonstrated that left ventricular end-systolic diameters (LVDs) (area under the curve: AUC = 0.660) and EFs (AUC = 0.797) had moderate predictive value for cardiac irAEs. Kaplan-Meier analysis showed a higher probability of cardiac irAEs in patients with LVDs and EFs beyond specific thresholds (p < 0.01). Poisson regression analysis indicated a decreasing risk of cardiac irAEs over time after ICI initiation.
conclusionBaseline echocardiographic parameters, particularly LVDs and EFs, can be useful predictors of cardiac irAEs in patients receiving ICI therapy. Early echocardiographic evaluation may facilitate risk stratification and improve monitoring strategies for cardiac irAEs. CLINICAL TRIAL REGISTRATION NUMBER: UMIN000023840.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.